Drug Profile
Inodiftagene vixteplasmid - Chemomab Therapeutics
Alternative Names: BC-819; BC-819/PEI; Diphtheria-toxin-A-H19; DTA-H19; DTA-H19/PEILatest Information Update: 24 Mar 2021
Price :
$50
*
At a glance
- Originator BioCancell Therapeutics
- Developer Anchiano Therapeutics; Chemomab Therapeutics
- Class Antineoplastics; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bladder cancer; Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 16 Mar 2021 Anchiano Therapeutics has been merged with Chemomab and changed its name to Chemomab Therapeutics
- 15 Nov 2019 Anchiano Therapeutics discontinues the phase II Codex trial in Bladder cancer in USA due low probability of surpassing the pre-defined futility threshold
- 08 Mar 2019 Anchiano Therapeutics terminates phase-IIb trial in Pancreatic cancer (Combination therapy, First-line therapy, Late-stage disease) in Europe, Israel, USA (Intratumoural) (NCT01413087)